
QuidelOrtho Corporation
QDELNASDAQHealthcareMedical - Specialties
Previous close
$14.74
−$0.11 · -0.74%
QDEL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
47
Fair Value
Momentum
43
Neutral
Sentiment
55
Mixed
Risk resilience
38
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteQuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Brian J. Blaser
- Listed since
- Feb 1, 1991
- Employees
- 6,500
Market position
Day range
Current $14.74
52-week range
Current $14.74
- Open
- $14.965
- Previous close
- $14.85
- Volume
- 2.02M
- 1× average
- Average volume
- 2.02M
- Average daily volume
- Market cap
- 1.01B USD
- Beta
- 0.69
- Market reference 1
- 50-day average
- $15.75
- -6.41% below average
- 200-day average
- $19.8511
- -25.75% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 4.65B USD
- EV / EBITDA
- -9.53×
- Earnings yield
- -56.97%
- Free cash flow yield
- -4.18%
Profitability & efficiency
- Return on equity
- -58.93%
- Return on assets
- -19.62%
- Return on invested capital
- -18.34%
Financial health
- Current ratio
- 1.5×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.73B USD | 2.78B USD | 3B USD | 3.27B USD | 1.7B USD |
| Cost of goods sold | 1.46B USD | 1.5B USD | 1.5B USD | 1.33B USD | 420.3M USD |
| Gross profit | 1.27B USD | 1.29B USD | 1.5B USD | 1.94B USD | 1.28B USD |
| Research and development | 186.2M USD | 218.7M USD | 246.8M USD | 187.9M USD | 95.7M USD |
| Selling, general, and administrative | 746.3M USD | 766.8M USD | 763.2M USD | 621M USD | 239.6M USD |
| Operating expenses | 2.19B USD | 3.25B USD | 1.36B USD | 1.09B USD | 372.3M USD |
| Interest income | — | — | 2.2M USD | 1.3M USD | 300K USD |
| Interest expense | 177.6M USD | 188.3M USD | 178.9M USD | 74.5M USD | 700K USD |
| Depreciation and amortization | 442M USD | 453.4M USD | 457.2M USD | 283.6M USD | 52.7M USD |
| Operating income | −919.2M USD | −1.96B USD | 139.1M USD | 843.7M USD | 906M USD |
| Net income | −1.13B USD | −2.05B USD | −10.1M USD | 548.7M USD | 704.2M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
QDEL news
QDEL peers
ETFs holding QDEL
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR60.53M0.05%111.19B USD0.06%$147.31+0.64%
Avantis U.S. Small Cap Value ETFAVUV47.73M0.15%31.27B USD0.25%$126.45+0.66%
Vanguard Morningstar Total Stock Market ETFVTI36.44M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB26.28M0.01%183.4B USD0.03%$304.76+0.64%
iShares Russell 2000 ETFIWM26.26M0.03%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Small-Cap Value ETFVBR16.7M0.02%68.3B USD0.05%$249.18+0.68%
Vanguard Extended Market ETFVXF13.2M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN9.54M0.07%14.66B USD0.24%$224.81+0.45%
iShares Core S&P Small-Cap ETFIJR- Market value
- 60.53M
- Weight
- 0.05%
- AUM
- 111.19B USD
- Expense ratio
- 0.06%
- Price / 1D
- $147.31+0.64%
Avantis U.S. Small Cap Value ETFAVUV- Market value
- 47.73M
- Weight
- 0.15%
- AUM
- 31.27B USD
- Expense ratio
- 0.25%
- Price / 1D
- $126.45+0.66%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 36.44M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 26.28M
- Weight
- 0.01%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
iShares Russell 2000 ETFIWM- Market value
- 26.26M
- Weight
- 0.03%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 16.7M
- Weight
- 0.02%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
Vanguard Extended Market ETFVXF- Market value
- 13.2M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 9.54M
- Weight
- 0.07%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Continue in GoAI
Research QDELresearch.disclaimer











